Luo Zhongchi, Yu Mei, Smith S David, Kritzer Mary, Du Congwu, Ma Yu, Volkow Nora D, Glass Peter S, Benveniste Helene
Departments of Biomedical Engineering, State University of New York at Stony Brook, Stony Brook, New York, USA.
Anesth Analg. 2009 Jan;108(1):334-44. doi: 10.1213/ane.0b013e31818e0d34.
Lidocaine can alleviate acute as well as chronic neuropathic pain at very low plasma concentrations in humans and laboratory animals. The mechanism(s) underlying lidocaine's analgesic effect when administered systemically is poorly understood but clearly not related to interruption of peripheral nerve conduction. Other targets for lidocaine's analgesic action(s) have been suggested, including sodium channels and other receptor sites in the central rather than peripheral nervous system. To our knowledge, the effect of lidocaine on the brain's functional response to pain has never been investigated. Here, we therefore characterized the effect of systemic lidocaine on the brain's response to innocuous and acute noxious stimulation in the rat using functional magnetic resonance imaging (fMRI).
Alpha-chloralose anesthetized rats underwent fMRI to quantify brain activation patterns in response to innocuous and noxious forepaw stimulation before and after IV administration of lidocaine.
Innocuous forepaw stimulation elicited brain activation only in the contralateral primary somatosensory (S1) cortex. Acute noxious forepaw stimulation induced activation in additional brain areas associated with pain perception, including the secondary somatosensory cortex (S2), thalamus, insula and limbic regions. Lidocaine administered at IV doses of either 1 mg/kg, 4 mg/kg or 10 mg/kg did not abolish or diminish brain activation in response to innocuous or noxious stimulation. In fact, IV doses of 4 mg/kg and 10 mg/kg lidocaine enhanced S1 and S2 responses to acute nociceptive stimulation, increasing the activated cortical volume by 50%-60%.
The analgesic action of systemic lidocaine in acute pain is not reflected in a straightforward interruption of pain-induced fMRI brain activation as has been observed with opioids. The enhancement of cortical fMRI responses to acute pain by lidocaine observed here has also been reported for cocaine. We recently showed that both lidocaine and cocaine increased intracellular calcium concentrations in cortex, suggesting that this pharmacological effect could account for the enhanced sensitivity to somatosensory stimulation. As our model only measured physiological acute pain, it will be important to also test the response of these same pathways to lidocaine in a model of neuropathic pain to further investigate lidocaine's analgesic mechanism of action.
利多卡因在人体和实验动物体内以非常低的血浆浓度即可缓解急性和慢性神经性疼痛。全身给药时利多卡因镇痛作用的机制尚不清楚,但显然与外周神经传导的中断无关。有人提出了利多卡因镇痛作用的其他靶点,包括中枢而非外周神经系统中的钠通道和其他受体位点。据我们所知,利多卡因对大脑疼痛功能反应的影响从未被研究过。因此,在这里我们使用功能磁共振成像(fMRI)来表征全身利多卡因对大鼠大脑对无害和急性有害刺激的反应的影响。
用α-氯醛糖麻醉大鼠,在静脉注射利多卡因前后进行fMRI,以量化大脑对无害和有害前爪刺激的激活模式。
无害前爪刺激仅在对侧初级躯体感觉(S1)皮层引起大脑激活。急性有害前爪刺激在与疼痛感知相关的其他脑区诱导激活,包括次级躯体感觉皮层(S2)、丘脑、岛叶和边缘区域。静脉注射1mg/kg、4mg/kg或10mg/kg剂量的利多卡因并没有消除或减弱大脑对无害或有害刺激的激活。事实上,静脉注射4mg/kg和10mg/kg剂量的利多卡因增强了S1和S2对急性伤害性刺激的反应,使激活的皮质体积增加了50%-60%。
全身利多卡因在急性疼痛中的镇痛作用并不像阿片类药物那样直接表现为疼痛诱导的fMRI大脑激活的中断。这里观察到的利多卡因增强皮层fMRI对急性疼痛的反应在可卡因中也有报道。我们最近表明,利多卡因和可卡因都增加了皮层细胞内钙浓度,表明这种药理作用可能解释了对躯体感觉刺激的敏感性增强。由于我们的模型仅测量生理性急性疼痛,因此在神经性疼痛模型中测试这些相同通路对利多卡因的反应以进一步研究利多卡因的镇痛作用机制也很重要。